AlphAIalphai — Financial news for AI agents
BenzingaSEP 302 min read$PYPD

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress - PolyPid (NASDAQ:PYPD)

PETACH TIKVA, Israel, Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- PolyPid Ltd. ( NASDAQ:PYPD ) ( "PolyPid" or the "Company" ) , a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dr. Shmuel Sharoni will present the topline results from the Company's successful ...

Original reporting
Benzinga · Globe Newswire
Published Sep 30, 2025, 12:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 1, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress - PolyPid (NASDAQ:PYPD) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$PYPDBullishHigh
01

Why it matters

Successful topline results are expected to positively influence stock performance and investor confidence.

02

Market read

The announcement is highly relevant for biotech investors and could influence stock prices and sector sentiment.

03

What to watch

Regulatory approval processes and market acceptance post-trial are critical; delays or setbacks could negate initial positive sentiment.

Timing: immediate, as the presentation is scheduled for 2025-10-15

Background

PolyPid is a late-stage biopharma company focused on surgical infection prevention. The upcoming presentation of Phase 3 results is a key milestone.

Company-level read

Ticker impact

$PYPDBullishHigh confidence
Context

The news pertains directly to PolyPid's upcoming presentation of positive Phase 3 trial results, which is highly relevant for investors and traders.

Expected impact

Potential short-term upward movement of 10-15% following the announcement, contingent on market reception.

Evidence & confidence

Successful Phase 3 topline results are a significant catalyst, especially for a biotech company nearing commercialization. The market's positive response is probable given the trial's success.

Market effects

Sector

The biotech sector may experience increased investor interest, especially in companies with promising late-stage trial results.

Regional

Primarily affects US and Israeli biotech markets, with potential spillover to global biotech indices.

Global

Moderate, as biotech news can influence global healthcare investment trends.

Counterpoint

What could challenge this read

Market may have already priced in the positive trial results, leading to limited upside or a potential sell-the-news reaction.

Key entities

  • Company
    PolyPid Ltd.

    Biopharmaceutical company developing infection prevention solutions.

  • Presenter
    Dr. Shmuel Sharoni

    Lead researcher presenting the trial results.

Read at source← All news

Related articles

AUG 19
HighAI 8/10

PolyPid (PYPD) Q2 2026 Earnings Call Transcript

PolyPid (PYPD) reported Q2 2026 milestones: FDA accepted its NDA for D-PLEX100 with Priority Review, setting a PDUFA goal date of November 28, 2026. The company also signed a $320M+ commercialization deal with Azurity Pharmaceuticals for the U.S. and Canada, including upfront payments, milestones, and royalties. PolyPid plans to submit an MAA to the EMA in Q3 2026 and expects a U.S. launch in early 2027.

yahoo.com3 min
AUG 14
$PYPDMed

PolyPid Ltd. Q2 2026 Earnings Call Summary

PolyPid said the FDA accepted its D-PLEX100 NDA with Priority Review and no filing issues, targeting a PDUFA date of Nov. 28, 2026. It signed an exclusive U.S. and Canada commercialization deal with Azurity, including upfront and tiered royalties plus a transfer price for retained manufacturing units. PolyPid expects a U.S. launch in early 2027 and $30M in milestone payments.

yahoo.com6 min
AUG 12
$PYPDHighAI 9/10

PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PolyPid Ltd. (Nasdaq: PYPD) said the FDA accepted its D-PLEX100 NDA for priority review for preventing surgical site infections in abdominal colorectal surgery, with a PDUFA goal date of Nov. 28, 2026. PolyPid entered an exclusive U.S. and Canada commercialization partnership with Azurity, receiving $30 million upfront and near-term milestones, plus tiered mid-teen to mid-twenties royalties. Q2 2026 net loss was $7.8M.

finanznachrichten.de7 min
AUG 12
$PYPDHigh

PolyPid Ltd. (PYPD): Financial results for Q2 2026

PolyPid Ltd. (PYPD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Co

SEC EDGAR 6-K2 min
JUL 29
$PYPDMedAI 8/10

PolyPid Ltd.: PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX100

PolyPid (Nasdaq: PYPD) said the FDA accepted its NDA for D-PLEX100 to prevent surgical site infections in abdominal colorectal surgery and granted Priority Review. The PDUFA target action date is Nov. 28, 2026. FDA found no filing review issues. Acceptance triggers a $15 million milestone from Azurity, completing $30 million in upfront and near-term milestones.

finanznachrichten.de2 min
JUL 24
$PYPDMedAI 8/10

Antibacterial Drug Partnership Accelerates PolyPid Commercial Path

PolyPid Ltd. (PYPD) said it signed an exclusive commercialization deal with Azurity Pharmaceuticals for D-PLEX100 to prevent abdominal surgical site infections in the U.S. and Canada. PolyPid gets $15M upfront, $15M on FDA NDA acceptance, and up to $300M in milestones. Deal follows Phase 3 SHIELD II results; U.S. launch targeted Q1 2027. Analysts at Roth and H.C. Wainwright set Buy ratings and $9 and $13 targets.

streetwisereports.com7 min